- Home
- IPSC vs ARCT Comparison
IPSC vs ARCT Comparison
Compare IPSC & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPSC | ARCT |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.7M | 192.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | IPSC | ARCT |
|---|---|---|
| Price | $2.33 | $7.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $3.50 | ★ $38.44 |
| AVG Volume (30 Days) | ★ 2.9M | 515.0K |
| Earning Date | 03-18-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $113,337,000.00 | $97,601,000.00 |
| Revenue This Year | $1,590.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4122.69 | N/A |
| 52 Week Low | $0.34 | $5.85 |
| 52 Week High | $2.71 | $24.17 |
Technical Indicators
Market Signals| Indicator | IPSC | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 65.56 | 52.46 |
| Support Level | $2.08 | $7.27 |
| Resistance Level | $2.71 | $7.89 |
| Average True Range (ATR) | 0.33 | 0.37 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 67.24 | 56.30 |
Price Performance
Historical ComparisonAbout IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.